Eosinophilic Esophagitis Market – By Drug Class, By Route of Administration, By Age Group, By Distribution Channel & Global Forecast, 2025 – 2034

Eosinophilic Esophagitis Market Size

The global eosinophilic esophagitis market size was valued at USD 366.2 million in 2024 and is estimated to grow at a CAGR of 31.4% from 2025 to 2034. The market continues to expand because of the increased rates and incidence of eosinophilic esophagitis. Eosinophilic esophagitis is characterized as an immune system disease and is evolving into a medical condition. This leads to the abnormal growth of eosinophils, or a type of white blood cell, in the gut, causing the esophagus to become inflamed or injured.
 

This abnormal growth is caused by foods, allergens, or acid reflux. Eosinophilic esophagitis is an ailment that is becoming increasingly widespread, especially in Western countries. It chiefly occurs in young adults and children, although people of all ages can be affected as well. In the American Journal of Gastroenterology, research was published stating that the number of eosinophilic esophagitis cases in the U.S. is believed to be as high as 56 per 100,000 adults. Recent research indicated an increasing prevalence of the disease in Europe, particularly Sweden and the UK.

In addition, the introduction of target-specific drugs and new therapeutic options will further the growth of the market alongside the current increased target-specific medicine and eosinophilic esophagitis awareness. For instance, a poll carried out by Deloitte in 2021 revealed that around 30% of primary care practitioners and gastroenterologists had turned for the better in respect to educational programs and scientific publications on autoimmune esophagitis over the past few years. Market progress is sustained by the increase in awareness among medical staff and patients about the completely new therapeutic arsenal and its consequent improved results for patient treatment.
 

Eosinophilic Esophagitis Market Trends

• The introduction of new tools such as non-invasive biomarkers and developing techniques such as endoscopy have improved the diagnosis and management of living with eosinophilic esophagitis, and this is bound to have a positive impact on the market.
   
• With the approval of new drugs by regulatory bodies like the U.S. FDA or by the European Medicines Agency (EMA), which directly impact the market with more therapies available for patients and thus make treatment more accessible. For example, Tezepelumab, an anti-thymic stromal lymphopoietin (TSLP) biologic, is being investigated for use in the treatment of eosinophilic esophagitis. It is still undergoing trials, hence, is not yet approved for eosinophilic esophagitis; however, it hints at increasing enthusiasm for biologic therapies.
   
• Thus, innovation in the market is fueled by the ongoing clinical trials of new drug formulations.
   

Eosinophilic Esophagitis Market Analysis

Based on drug class, the global market is divided into biologics, corticosteroids, proton pump inhibitors, immunomodulators, and other drug classes. The corticosteroids segment dominated the market and was valued at USD 137.3 million in 2024.
 

• Fluticasone propionate and budesonide are recognized as effective medications for eosinophilic esophagitis illness to quench inflammation. Some of the other symptoms of eosinophilic esophagitis, like dysphagia (difficulty swallowing), chest pain, and food impact, can be treated quickly using corticosteroids, which put them as the first choice in numerous cases.
   
• Moreover, their combination treatment with diet and therapy is also quite successful, which only adds to their popularity.
   
• Furthermore, the increase in disease management along with awareness in the developing regions has led to an increased usage of corticosteroids, boosting market growth.

Based on the route of administration, the eosinophilic esophagitis market is categorized into injectable, oral, injectable, and topical. The oral segment accounted for the highest market share of 41.5% in 2024.
 

• Compared to intravenous (IV) routes, self-administration of drugs through the mouth is considerably easier for patients, which is less intimidating.
   
• Unlike systemic treatment that has the potential to cause significant side effects over a prolonged period, oral therapy has the advantage of safer long-term use of targeting esophagus-specific medication to lessen side effects on the body.
   
• The development of novel and target IL-4, IL-5, or IL-13 have advanced the range of medications available alongside small molecules, augmenting eosinophilic esophagitis.
   

Based on age group, the global eosinophilic esophagitis market is categorized into pediatric, adults, and geriatric. The adults segment dominated the market in 2024 and is growing with a CAGR of 31.5% during the analysis period.
 

• Adults are increasingly being diagnosed with eosinophilic esophagitis, fueling market growth. This uptick in adult diagnoses can be attributed to enhanced diagnostic methods, heightened awareness, and a deeper comprehension of the disease's implications extending beyond childhood.
   
• The disease is more frequently reported both among patients and doctors, and this trend is likely to facilitate the development of the market.
   
• Furthermore, dietary and environmental allergens are believed to increase the chances of developing eosinophilic esophagitis, particularly in adults. Factors such as genetics, environmental allergens, and diet are some of the determinants that are becoming more and more associated with eosinophilic esophagitis in adults.
   
• Thus, the increased demand for new pharmaceutical therapies is expected to drive the market growth for eosinophilic esophagitis, as the requirements for their prevalence continue to rise.
   

Based on distribution channel, the eosinophilic esophagitis market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2024 and is anticipated to reach USD 2.1 billion by 2034.
 

• As awareness of eosinophilic esophagitis rises, a growing number of patients are pursuing diagnosis and treatment, usually starting in hospital settings. Hospitals are increasingly employing advanced diagnostic techniques, including endoscopy and biopsy, which in turn drives the demand for specialized medications, fueling segmental growth.
   
• Moreover, hospital pharmacies frequently serve as the initial touchpoint for patients accessing novel treatments for eosinophilic esophagitis, including biologic therapies like Dupixent (dupilumab).
   
• Alongside expanding awareness, the availability of specialized medication is rapidly increasing. The integration of hospitalization is enabling advanced diagnostic techniques such as endoscopies and biopsies to be utilized.
   
• This, in turn, enhances the overall healthcare infrastructure, allowing for greater growth potential across the board.

In 2024, the U.S. held a significant position in the North America eosinophilic esophagitis market and was valued at USD 151.3 million.
 

• The reason eosinophilic esophagitis is one of the most common conditions in U.S. is because it is easily recognizable. Also, the condition is being increasingly found in the younger population. All these factors are helping in the growth of the market.
   
• Another growing concern is that U.S. spending on health continues to go up, with focused care spending more on chronic and rare conditions like eosinophilic esophagitis.
   
• Patients increasingly search for better long-term management options, while healthcare providers are spending time on the research and development of effective solutions. Additionally, there has been increased investment in eosinophilic esophagitis pathophysiology, diagnosis, and treatment research.
   
• Consequently, there is an increasing number of clinical trials and studies in the U.S. targeting the condition along with new therapeutics being formed.
   

Germany shows strong growth potential in the eosinophilic esophagitis market.
 

• There has also been an increase in the diagnosis of eosinophilic esophagitis in Germany and other parts of Europe. As stated by the European Journal of Gastroenterology & Hepatology research that was published in 2021, Germany is estimated to have an eosinophilic esophagitis incidence of 1 in 5, and for Europe, the number ranges between 100-5 subtitles.
   
• In addition, Germany boasts an advanced healthcare system that makes endoscopic services readily available to its population.
   
• The German medical community has been actively promoting the early diagnosis of eosinophilic esophagitis, which requires the employment of endoscopic procedures for precise evaluation and biopsy.
   

The eosinophilic esophagitis market in Asia Pacific is estimated to grow at a CAGR of 31.8% over the next few years.
 

• China’s healthcare system is improving significantly and has been granting more access to techniques such as endoscopy, as well as biopsy procedures necessary to diagnose eosinophilic esophagitis, that is needed to undergo for diagnosis.
   
• Through researching and funding in key areas such as China, it is focusing on rare diseases and chronic types such as eosinophilic esophagitis. The government has been supporting clinical trials as well.
   
• The faster urbanization and an ever-increasing geriatric population push more people to take up sedentary lifestyles causing factors like obesity and gastrointestinal diseases to worsen. This creates an increase in demand for treatment, further propelling market growth.
   

Brazil eosinophilic esophagitis market is projected to witness growth in coming years.
 

• The transforming dietary habits in Brazil, where there is an increase consumption of processed food, and allergens have led to a rise of eosinophilic esophagitis, combined with over exposure, the environmental factors allow an easy increase in eosinophilic esophagitis.
   
• The government has also been trying to enhance chronic disease management in Brazil, aiming at conditions such as eosinophilic esophagitis, in addition to changing the diagnostic tools and providing finances for the chronic conditions have the potential of evolving the market.
   

Saudi Arabia is anticipated to grow in the Middle East and African eosinophilic esophagitis market.
 

• Among other allergies Saudi Arabia has also seen an increase in food allergies which are the reasons of eosinophilic esophagitis becoming more and more common. These allergies are on the rise and as a result there is significantly increased incidence of eosinophilic esophagitis which in return increases the population of patients who seek medical help.
   
• In addition, Saudi Arabia has been modernizing its medical care which has resulted in stronger diagnostic techniques and improved patient management. Strengthened awareness towards eosinophilic esophagitis among the health professionals as well as the public serves to hasten diagnosis and treatment thereby boosting the market.
   

Eosinophilic Esophagitis Market Share

The market is populated with an array of international pharmaceutical and biotechnology companies as well as regional companies providing the therapy plant. The well-established pharmaceutical companies have developed varying treatment options for eosinophilic esophagitis which are globally marketed under different names. Companies are concentrating on product differentiation, obtaining permits, and forming strategic alliances to solidify their position in this competitive environment.
 

Eosinophilic Esophagitis Market Companies

Players operating in the eosinophilic esophagitis industry are as mentioned below:

• Allakos
• Arena Pharmaceuticals
• AstraZeneca
• Cipla
• Ellodi Pharmaceuticals
• EsoCap
• GlaxoSmithKline
• Revolo Biotherapeutics
• Sanofi
• Sun Pharmaceutical
• Takeda Pharmaceutical Company
• Teva Pharmaceutical 
   

USPs for top market players:

• Global reach of companies with extensive experience in gastroenterology.
   
• Innovative pipeline with collaboration among top pharmaceutical companies.
   
• Strong global presence with rapid market penetration and access in key regions.
   

Eosinophilic Esophagitis Industry News

• In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), for people 11 years and older with eosinophilic esophagitis. This helped the company expand its product range.
   
• In January 2024, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis. This approval aimed to broaden the treatment availability, complementing existing therapies for eosinophilic esophagitis.
   

The eosinophilic esophagitis market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Biologics
• Corticosteroids
• Proton pump inhibitors
• Immunomodulators
• Other drug class

Market, By Route of Administration

• Oral
• Injectable
• Topical

Market, By Age Group

• Pediatric
• Adults
• Geriatric

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE